全球即时分子诊断市场 – 行业趋势及 2029 年预测

全球即时分子诊断市场分析及规模

研究人员和科学家越来越关注应用各种测试来检测 DNA 或 RNA 中的特定序列，这导致了即时分子诊断的广泛应用。这些即时分子诊断测试有助于诊断可能导致或影响患上特定疾病的基因或染色体的变化。在这种情况下，任何变化都可能导致癌症等疾病。                                        

• Data Bridge Market Research 分析称，在预测期内，即时分子诊断市场预计将经历 13.40% 的复合年增长率。这意味着市场价值（2021 年为 30.4635 亿美元）到 2029 年将飙升至 83.30753 亿美元。由于全球癌症发病率不断上升，“肿瘤学”在即时分子诊断市场的产品类型细分市场中占据主导地位。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

报告范围和市场细分

Global Point of Care Molecular Diagnostics Market Definition

Point of care molecular diagnostics are the diagnostic tests that are conducted to diagnose and detect infectious diseases in patients these are fast, reliable and offer a greater degree of reach. Owing to their faster results, the point of care molecular diagnostics help to suggest the correct treatment options available for the patients.              

Point of Care Molecular Diagnostics Market Dynamics

Drivers

• Rising prevalence of infections

Growing incidence rate of infectious diseases and acute and chronic disorders is one of the major factors fostering the growth of the market. For example- increasing prevalence of cancer and HIV aids is directly influencing the market growth rate. In 2019, according to the Department of Health & Human Services, more than 38 million people were suffering from HIV aids.  

• Research and development proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies being conducted for the development of emergency healthcare services is also bolstering the market growth rate.

• Growing investment for healthcare facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.

Opportunities

Furthermore, upsurge in the public-private funding for target research activities, rising conferences and exhibitions to raise awareness of robotic systems in pharmaceutical manufacturing, rising number of road accidents and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2022 to 2029. Additionally, increased demand for collaborative robots in manufacturing facilities, rising internet penetration rate, rising need for home healthcare services and increasing per capita expenditure on health care will further expand the market's growth rate in the future. 

Restraints/Challenges Global Point of Care Molecular Diagnostics Market

On the other hand, high cost associated with the research and development proficiencies, limited infrastructural facilities and dearth of awareness in the backward economies are expected to obstruct market growth. Also, lack of favourable reimbursement scenario and technology penetration in the developing economies, stringent regulatory hurdles pertaining to the point of care diagnostic test kits, lack of alignment with definitive central lab methods and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2022-2029.

This point of care molecular diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the point of care molecular diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Point of Care Molecular Diagnostics Market

COVID-19 has stimulated the market growth rate in the upward direction. Increasing number of patients and booming hospitalization rate owing to the spread of virus is one of the biggest factors responsible for pushing up the market growth rate. Growing focus of the healthcare institutions to provide the best of facilities to the patients ensured a good run of the market in this pandemic. Further, rising global demand for diagnostic kits to rapidly detect the disease in this period created lucrative market growth opportunities. Moreover, increasing prevalence of other respiratory illnesses across the globe and improved access to point-of-care devices through online platforms further pushed the growth rate of the market.  

Recent Developments

• In February 2022, Sense Biodetection entered into a strategic agreement with Una Health (Una) for the United Kingdom distribution of the Veros Covid-19 test.
• In December 2021, FIND invested USD 21 million in Biomeme, Bioneer, Qlife, and SD Biosensor to accelerate the development, manufacturing, and launch of affordable point-of-care molecular diagnostic platforms that can detect multiple pathogens that cause diseases including COVID-19. 

Global Point of Care Molecular Diagnostics Market Scope

The point of care molecular diagnostics market is segmented on the basis of product and services, technology, test location, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and services

• Assays and Kits
• Instruments/Analyzers
• Software and Services

Based on product & services, point of care molecular diagnostics market is segmented into assays and kits, instruments/analyzers, software and services.

Technology

• Polymerase Chain Reaction-Based
• Genetic Sequencing-Based
• Hybridization-Based
• Microarray-Based
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Others

Point of care molecular diagnostics market has also been segmented based on the technology into PCR-based, genetic sequencing-based, hybridization-based, microarray-based, isothermal nucleic acid amplification technology (INAAT) and others.

Test location

• Over The Counter
• Point of Care

Based on test location, point of care molecular diagnostics market is segmented into over the counter and point of care.

Application

• Respiratory Diseases
• Sexually Transmitted Diseases
• Hospital-Acquired Infections
• Oncology
• Hepatitis
• Hematology
• Prenatal Testing
• Endocrinology
• Others

Based on application, point of care molecular diagnostics market is segmented into respiratory diseases, sexually transmitted diseases, hospital-acquired infections, oncology, hepatitis, hematology, prenatal testing, endocrinology and others.

End user

• Physician Offices
• Hospital Emergency Departments and Intensive Care Units
• Research Institutes
• Home-Care
• Decentralized Labs
• Assisted Living Healthcare Facilities
• Others

Based on end-user, point of care molecular diagnostics market is segmented into physician offices, hospital emergency departments and intensive care units, research institutes, home-care, decentralized labs, assisted living healthcare facilities and others.

Point of Care Molecular Diagnostics Market Regional Analysis/Insights

The point of care molecular diagnostics market is analysed and market size insights and trends are provided by country, product and services, technology, test location, application and end user as referenced above.

The countries covered in the point of care molecular diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the point of care molecular diagnostics market because of the strong base of healthcare facilities, increased adoption of advanced point of care molecular diagnostics solutions to detect infections diseases and rising number of research activities in this region.  

Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, availability of the well-established infrastructure, improving rate of adoption of point of care molecular diagnostics in India and China and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

即时分子诊断市场还为您提供了每个国家/地区资本设备医疗保健支出增长、即时分子诊断市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对即时分子诊断市场的影响的详细市场分析。数据涵盖 2010-2020 年的历史时期。

竞争格局和即时分子诊断市场份额分析

即时分子诊断市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对即时分子诊断市场的关注有关。

临床分子诊断市场的一些主要参与者包括：

• 雅培（美国）
• 西门子医疗股份公司（德国）
• Quidel Corporation（美国）
• F. Hoffman-La Roche Ltd.（瑞士）
• 丹纳赫（美国）
• BD（美国）
• Chembio Diagnostics（美国）
• EKF 诊断（英国）
• Trinity Biotech plc（爱尔兰）
• 仪器实验室（美国）
• Nova Biomedical（美国）
• PTS Diagnostics（美国）
• Sekisui Diagnostics（美国）
• 赛默飞世尔科技（美国）
• 生物梅里埃公司（法国）
• DiaSorin SpA（意大利）
• AccuBioTech 有限公司 (中国)
• Meridian Bioscience（美国）
• Biocartis Bioscience（欧洲）
• GeneSTAT Molecular Diagnostics, LLC（美国）
• 泰尔茂株式会社 (日本)
• Grifols, SA（西班牙）

研究方法：全球即时诊断分子诊断市场

数据收集和基准年分析是使用具有大样本量的数据收集模块进行的。市场数据使用市场统计和连贯模型进行分析和估计。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。如需了解更多信息，请请求分析师致电或下拉询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请咨询我们的行业专家 https://www.databridgemarketresearch.com/zh/speak-to-analyst/?dbmr=global-point-of-care-molecular-diagnostics-market

SKU-26615